Corporate update from company developing NTLA-2002, a potential gene therapy for HAE
A series of updates were given on NTLA-2002, which is currently being trialled in patients with HAE, by the pharmaceutical company Intellia Therapeutics. The key updates shared with HAEi were:
- Additional data from the ongoing Phase 1/2 study of NTLA-2002 will be presented in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 on Sunday 15 June in Glasgow, United Kingdom. The presentation will include longer-term durability data from patients in the Phase 1 portion of the Phase 1/2 study.
- Enrollment is progressing in the global Phase 3 HAELO study, and the Company expects to complete enrollment in the third quarter of 2025.
- It is expected that new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study will be presented in the second half of 2025. The data will include patients who initially received a 25 mg dose or placebo and were subsequently given the 50 mg dose of NTLA-2002 selected for the Phase 3 study.
- The Company is on track to submit a Biologics License Application (BLA) in the second half of 2026.
Intellia President and Chief Executive Officer John Leonard MD, said: “Intellia is full steam ahead and making excellent progress across its clinical programs. Upcoming catalysts include longer-term data from the ongoing Phase 1 study of NTLA-2002 at the upcoming EAACI Congress in addition to updated data from the Phase 2 study of NTLA-2002 in the second half of 2025.”
(Source: Intellia)